<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094802/" ref="ordinalpos=3336&amp;ncbi_uid=2954009&amp;link_uid=PMC3094802" image-link="/pmc/articles/PMC3094802/figure/F3/" class="imagepopup">Fig. 3.  From: Notch <span class="highlight" style="background-color:">Signaling</span> Proteins: Legitimate Targets for Cancer Therapy. </a></div><br /><div class="p4l_captionBody">Diagram of putative therapeutic target in the Notch pathway. Notch signaling could be inhibited theoretically at many different levels. It is possible to (1) interfere with Notch-ligand interactions, (2) inhibit receptor activation, (3) promote Notch ubiquitination and degradation, (4) inhibit its translocation to the nuclear compartment and (5) inhibit NICD nuclear complex formation.</div></div>